LDS/Medical Tests/Epidermal Growth Factor Receptor (EGFR), IHC

Epidermal Growth Factor Receptor (EGFR), IHC

Epidermal Growth Factor is a protein that promotes epidermal cell (cells from the outer layer of skin) growth. EGF binds to the surface of epidermal cells to a protein called Epidermal Growth Factor Receptor (EGFR). When EGF binds to EGFR this triggers reactions that cause the cells to grow and multiply. The epidermal growth factor receptor (EGFR) is a cellular transmembrane receptor with tyrosine kinase enzymatic activity and can be found on the surface of many different types of cancer cells in high amounts. Therefore, in addition to its physiological function, EGFR plays a key role in human cancer. EGFR has been a therapeutic target for many cancers including lung cancer, colorectal cancer, breast cancer, thyroid cancer, and pancreatic cancer.

Non-small cell lung cancer (NSCLC) is a cancer that has been identified with high amounts of EGFR. Non-small cell lung cancer makes up the majority of lung cancers. This is significant because lung cancer is the leading cause of cancer death in men and women. In evaluation of treatment of NSCLC patients, tissue samples were evaluated for EGFR. It was noted in these studies that EGFR mutation is a relatively good predictor of treatment response. NSCLC patients that were positive for EGFR mutation were more likely to respond to therapies that target the EGFR pathway. In colorectal cancer, the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and panitumumab have good clinical activity in about 10% of patients with metastatic colorectal cancer that is resistant to chemotherapy. In breast cancer, EGFR levels are also high and are a good therapeutic target. Therefore, analysis for EGFR mutation is significant in therapeutic treatment and disease management.

  • Determine eligibility for therapies targeting epidermal growth factor receptor (EGFR)
  • Predict patient outcome in patients treated with EGFR antagonists
  • Disease monitoring
  • Positive (FISH): Appears to predict a greater likelihood of response to EGFR-targeted therapies
  • Negative (FISH): Are associated with a greater likelihood of drug resistance
  • Positive (IHC): For patients with NSCLC, results predict response for certain targeted therapies
  • Negative (IHC): May be predictive of drug resistance

Negative for mutation analyzed

Immunohistochemical Assay (IHC), Fluorescence In Situ Hybridization (FISH).

Tissue or Paraffin Block

Stability

  • Ambient: 12 months
  • Refrigerated: 12 months
  • Frozen: Unacceptable
Her-2/neu, B-RAF, K-RAS, EGFR mutation analysis, p53 by molecular method and by IHC, Ki67 by IHC, p63 by IHC for lung cancer, B-RAF mutation analysis (for colon cancer), Microsatellite Instability/HNPCC by molecular method and by IHC (for colon cancer), Septin 9 (*SEPT9*) for colon cancer, Methylated DNA Detection by Real-Time PCR (for lung cancer).
4-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login